CRIS Current Research Information System

CALZA, LEONARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.332
EU - Europa 9.356
AS - Asia 8.747
SA - Sud America 809
AF - Africa 605
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
AN - Antartide 1
Totale 30.866
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.254
CN - Cina 2.824
GB - Regno Unito 2.810
SG - Singapore 2.672
VN - Vietnam 1.379
DE - Germania 1.316
IT - Italia 1.138
UA - Ucraina 1.074
SE - Svezia 977
HK - Hong Kong 707
BR - Brasile 614
RU - Federazione Russa 610
IN - India 571
FR - Francia 441
IE - Irlanda 335
JP - Giappone 232
ZA - Sudafrica 224
EE - Estonia 175
NL - Olanda 151
KR - Corea 149
TG - Togo 120
SC - Seychelles 106
AR - Argentina 94
CI - Costa d'Avorio 93
FI - Finlandia 73
BG - Bulgaria 55
ID - Indonesia 50
JO - Giordania 40
AT - Austria 39
CH - Svizzera 36
MX - Messico 36
EC - Ecuador 31
CA - Canada 30
NG - Nigeria 26
PL - Polonia 23
GR - Grecia 22
BD - Bangladesh 20
BE - Belgio 20
LB - Libano 20
CL - Cile 19
CO - Colombia 19
ES - Italia 14
PY - Paraguay 13
IQ - Iraq 12
UZ - Uzbekistan 12
AU - Australia 10
IR - Iran 10
VE - Venezuela 10
LT - Lituania 9
RO - Romania 9
TR - Turchia 9
PT - Portogallo 8
EG - Egitto 7
KE - Kenya 7
MA - Marocco 6
PE - Perù 6
PH - Filippine 6
NP - Nepal 5
CZ - Repubblica Ceca 4
EU - Europa 4
PK - Pakistan 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
MY - Malesia 3
PA - Panama 3
SA - Arabia Saudita 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
HR - Croazia 2
IL - Israele 2
KW - Kuwait 2
KZ - Kazakistan 2
TL - Timor Orientale 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AQ - Antartide 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CG - Congo 1
CV - Capo Verde 1
GI - Gibilterra 1
GN - Guinea 1
GY - Guiana 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MS - Montserrat 1
MZ - Mozambico 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 30.857
Salva come PNG Salva come JPEG
Città #
Southend 2.518
Singapore 1.640
Fairfield 1.168
Ashburn 1.112
Jacksonville 771
Chandler 707
Hong Kong 703
Wilmington 615
Hefei 589
Santa Clara 582
Woodbridge 579
Princeton 556
Seattle 506
Houston 463
Dong Ket 417
Cambridge 395
Dublin 335
Ann Arbor 331
Boardman 315
Beijing 309
Nanjing 272
Westminster 255
Bologna 251
Padova 242
Ho Chi Minh City 228
Tokyo 224
Berlin 201
Hanoi 177
Los Angeles 165
Seoul 149
Saint Petersburg 130
Mülheim 126
Jinan 123
Lomé 120
Buffalo 111
Shenyang 109
Milan 105
San Diego 94
Abidjan 93
Medford 91
Mahé 90
Nanchang 85
Hebei 81
Redondo Beach 76
Changsha 73
Dallas 65
Tianjin 59
New York 58
Dearborn 54
Sofia 53
Florence 52
Verona 52
Jiaxing 50
Helsinki 49
The Dalles 49
Zhengzhou 49
São Paulo 47
Guangzhou 44
Norwalk 42
Amman 40
Falls Church 40
Olalla 40
Bengaluru 39
Des Moines 39
Hangzhou 39
Ningbo 37
Turin 37
Yubileyny 37
Redmond 36
Chicago 34
Kunming 34
Nuremberg 34
Shanghai 33
Frankfurt am Main 32
Lanzhou 31
Haikou 26
Abeokuta 24
Munich 24
Rio de Janeiro 24
Bühl 23
Phoenix 22
Rome 20
Brussels 19
London 19
Taizhou 18
Wuhan 18
Xi'an 18
Bremen 17
Falkenstein 17
Turku 17
Bern 16
Brooklyn 16
Haiphong 16
Qingdao 15
Shenzhen 15
Hải Dương 14
Jakarta 14
Redwood City 14
Stockholm 14
Taiyuan 14
Totale 20.041
Salva come PNG Salva come JPEG
Nome #
Restriction Factors expression decreases in HIV-1 patients after cART 233
Acute onset myopericarditis as unusual presentation of primary HIV infection 220
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 206
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 204
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 196
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 196
A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection. 194
A 2-year survey of bacteriologic profile and antimicrobial susceptibility levels of Enterococci in a large Italian teaching hospital. 194
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 180
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. 179
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 177
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 174
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients. 171
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues 169
Abacavir-induced febrile agranulocytosis and anaemia. 168
Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies 168
Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. 164
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 161
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 161
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 160
Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy 159
Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological, and imaging response of lung tuberculosis to specific treatment. Which role for linezolid? 159
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 158
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 158
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 156
Pancreotoxicity of propofol sedation during purulent meningitis. 155
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. 155
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 154
Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. 151
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. 151
Bone mass loss in patients with human immunodeficiency virus type 1 infection: association with male sex and protease inhibitor therapy 150
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. 150
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. 149
A prospective comparison of hepatotoxicity of the two currently available non-nucleoside reverse transcriptase inhibitors in a homogeneous case-mix of HIV-infected patients treated for the first time with efavirenz or nevirapine, according to their different baseline conditions 149
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 149
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 149
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 149
Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine 147
Molecular Bases of Osteoporosis in HIV: The Role of the Virus and Antiretroviral Therapy 147
Severe peripheral neuropathy with areflexic and flaccid quadriplegia complicating Legionnaires’ disease in an adult patient. 147
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 147
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 146
Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy 144
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. 143
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir 143
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 143
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 142
Methicillin-resistant staphylococci still susceptible to non-beta-lactam antibiotics. What clinical implications in nosocomially-acquired infections? 142
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 142
HIV and kidney: A dangerous liaison 142
Polyunsaturated ethyl esters on n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. 141
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. 141
First-line efavirenz versus lopinavir/ritonavir-based highly active antiretroviral therapy for naïve patients. 141
Legionnaires' disease associated with macular rash: two cases 141
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 141
Abacavir-lamivudina versus tenofovir-emtricitabina più atazanavir-ritonavir nella semplificazione dell'HAART per dislipidemia 141
Measles outbreak in the city of Bologna, December 2007 to May 2008 140
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 140
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS 139
Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. 138
Changing epidemiology of hepatitis A in the Bologna metropolitan area, northern Italy: importance of counselling and prophylactic measures for the male homo/bisexual population. 138
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 138
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 138
Primary Cytomegalovirus infection in otherwise healthy adults with Fever of Unknown Origin: a 3-year prospective survey 137
Aderenza alla terapia antiretrovirale "autogestita" dai pazienti alla metà della posologia giornaliera raccomandata. Inattesa efficacia immunologica e virologica a lungo termine 137
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 137
An observational study of subcutaneous multiple lipomatosis in patients receiving highly active antiretroviral therapy. Possible correlations with metabolic abnormalities and pathogenetic insights 136
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 136
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. 135
Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study. 135
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 134
Bladder carcinoma and HIV infection during the highly active antiretroviral therapy era: a rare, but intriguing association. Two case reports and literature review 133
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 133
An extremely different dysmetabolic profile between the two available nonucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. 132
Loss of bone mass in chronically HIV-infected patients. Significant association with male gender and protease inhibitor administration 132
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection. 132
Safety issues about nevirapine administration in HIV-infected pregnant women 131
Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration 131
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. 131
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. 130
Cardiovascular prevention in HIV-positive individuals on antiretroviral therapy.. The paradigm shift has already happened: Is it time to wake up and realise it? 129
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 129
Stabilizzazione a lungo termine dell'assetto virologico e immunologico dell'infezione da HIV in un "AIDS Presenter" seguito per oltre vent'anni, nonostante la mancata aderenza alla terapia antiretrovirale 128
Chron’s disease, rare association with selective IgA immunodeficiency, and development of life-threatening bacterial infections. 127
Metabolic alterations in human immunodeficiency virus-infected patients treated with antiretroviral therapy 126
Antiretroviral treatment and gynecomastia: which correlations? 126
First-line efavirenz- versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients 126
Diffuse skin spread of HIV-associated visceral leishmaniasis: cumbersome diagnostic and therapeutic issues 126
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 126
Sensitivity of methicillin-resistant Staphylococcus aureus (MRSA) to antimicrobial agents other than beta-lactams: profile and trend, 1998-2003 125
Antiretroviral therapy voluntarily taken at half-dosage, but fully effective after 6-10 years: a provocative issue for adherence requirements. Case report 125
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy 125
Comparison between switching therapy from protease inhibitors to an NNRTI and lipid-lowering therapy with pravastatin or bezafibratef for the management of HAART-related dyslipidemia 124
Renal toxicity associated with antiretroviral therapy 124
AIDS-associated atypical mycobacteriosis other than Mycobacterium avium-intracellulare: a 15-year survey of Mycobacterium kansasii and Mycobacterium xenopi 123
Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. 123
Concurrence of two different opportunistic mycoses complicated by visceral dissemination diagnosed in "AIDS Presenter" patients: candidiasis and cryptococcosis 122
Raltegravir use prospectically assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profile 122
Changing epidemiology of hepatitis A in Italy 121
HIV infection and the pancreas: risk factors and potential management guidelines 121
Totale 14.738
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.839
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.839
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.902 0 0 0 0 0 194 40 209 198 231 177 853
2021/20224.312 402 215 284 406 405 262 77 331 146 349 732 703
2022/20233.746 467 596 209 473 237 225 127 188 621 118 361 124
2023/2024867 72 156 63 98 66 158 51 62 25 64 23 29
2024/20254.519 118 901 407 359 976 204 251 89 38 202 81 893
2025/20265.836 709 1.187 1.261 1.003 1.264 412 0 0 0 0 0 0
Totale 31.301